Back to Authors

Yadav, Satya Prakash

https://orcid.org/0000-0002-0507-1786

Mayo Clinic

Department of Pediatrics, Pediatric Hematology Oncology & Bone Marrow Transplant Unit

Citations 1

Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation
Rastogi, Neha , Abraham, Roshini S. , Chadha, Ritu , Thakkar, Dhwanee, Kohli, Shruti, Nivargi, Sagar , Yadav, Satya Prakash

Journal of Pediatric Hematology/Oncology | November 17, 2017 | Volume: 40 | Issue: 6 | Pages: e383-e388

10.1097/mph.0000000000000995 Get It

Emberger syndrome with underlying guanine-adenine-thymine-adenine 2 (GATA2) mutation is a rare disorder and very few successful nonmyeloablative allogeneic hematopoietic stem cell transplants (HSCTs) have been reported. We report a case of Emberger syndrome with GATA2 mutation in a 9-year-old girl who presented with congenital sensorineural deafness, warts, lymphedema, and Myelodysplastic syndrome. Her sister had died of a similar illness. She underwent a nonmyeloablative matched related donor peripheral blood HSCT with rabbit antithymoglobulin (5 mg/kg), fludarabine (160 mg/m2), cyclophophamide (29 mg/kg), and total body irradiation (2 Gray). Graft versus host disease prophylaxis consisted of tacrolimus and mycophenolate moefetil. She had neutrophil engraftment on day+15 and fully donor chimerism by day+30. She developed limited chronic skin graft versus host disease on tapering off immunosuppression. She is disease free on day+475. The review of literature showed a total of 28 patients with GATA2 mutation have undergone HSCT mostly nonmyeloablative and overall survival is 75%. Nonmyeloablatove HSCT is feasible and safe for the patients with GATA2 mutation.